Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically ...
GlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the European Society of Medical Oncology (ESMO) congress in Barcelona gets underway.
ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304) ESMO 2024: HARMONY: A Phase II Study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback